Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04682964
Other study ID # TashkentPediatricMI
Secondary ID
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date October 2, 2020
Est. completion date December 31, 2024

Study information

Verified date December 2023
Source Tashkent Pediatric Medical Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The patients received bacteriophage therapy with a liquid piobacteriophage complex (liquid pyobacteriophage complex - PCL). PСL was administered via nebulizer inhalation to irrigate the tonsil mucosa. A total of 5 ml of PCL was inhaled for 10 minutes every 5 days. The drug causes the lysis of certain bacteria, including staphylococcus, enterococcus, streptococcus, enteropathogenic E. coli, Proteus vulgaris, Proteus mirabilis, Pseudomonas aeruginosa, Klebsiella pneumoniae and Klebsiella oxytoca. The choice of this drug was based on bacteriological studies.


Description:

Comprehensive outpatient treatment was based on standard clinical guidelines, and symptomatic treatment was performed. On the first day of diagnosis, patients were prescribed complex antibacterial therapy on the basis of possible causative agents. Subsequently, antibiotic therapy was adjusted based on the results of the bacteriological examinations. A total of 67 patients received bacteriophage therapy using a liquid complex of pyobacteriophages (pyobacteriophage complex liquid - PСL). PСL was administered via nebulizer inhalation to irrigate the mucous membranes of the tonsils. In total, 5 ml of PCL was inhaled for up to 10 minutes once every 5 days. The drug causes lysis of specific bacteria including Staphylococcus, Enterococcus, Streptococcus, enteropathogenic Escherichia coli, Proteus vulgaris, Proteus mirabilis, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Klebsiella oxytoca. The drug is recommended for use for diseases of the ear, throat, nose, respiratory tract and lungs; inflammation of the sinuses and middle ear; tonsillitis; pharyngitis; laryngitis; tracheitis; bronchitis; pneumonia, pleurisy; and other inflammatory diseases. The choice of this drug was based on bacteriological studies.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 128
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 3 Years to 14 Years
Eligibility Inclusion Criteria: - children from 3 to 14 years old. - children with sore throat. - children diagnosed with acute tonsillitis. - children diagnosed with acute respiratory infection (rhinitis, sinusitis, nasopharyngitis). - children with the opportunity to visit the outpatient clinic. - children with the ability to receive inhalation therapy. - children from parents (or guardians) who have given written permission to conduct clinical and laboratory research. Exclusion Criteria: - children under 3 years old and over 14 years old. - children receiving hospital treatment. - children with acute respiratory tract diseases (bronchitis, pneumonia, pleurisy). - children with ?hronic respiratory tract diseases (bronchitis, pneumonia). - children who are allergic to antibiotics. - children with cancer, immunological and hematological diseases. - children with severe psychological illnesses (schizophrenia, mental retardation, etc.) - children with cancer, immunological and hematological diseases. - children with tuberculosis.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Nebulizer inhalation irrigation of the mucous membranes of the tonsils with a bacteriophage.
Bacteriophage therapy using a liquid complex of pyobacteriophages (pyobacteriophage complex liquid - P?L). P?L was administered via nebulizer inhalation to irrigate the mucous membranes of the tonsils. In total, 5 ml of PCL was inhaled for up to 10 minutes once every 5 days.

Locations

Country Name City State
Uzbekistan Tashkent Pediatric Medical Institute Tashkent

Sponsors (1)

Lead Sponsor Collaborator
Tashkent Pediatric Medical Institute

Country where clinical trial is conducted

Uzbekistan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical observation of sick children. Children with clinically diagnosed acute tonsillitis are examined. The clinical study will be carried out on an outpatient basis in cooperation with the clinic of the Tashkent Pediatric Medical Institute. Prior to the study, written permission will be obtained from the parents or guardians of the children to participate in the study. Investigated: anamnesis of the child, the course of the disease, complaints of parents about the child's condition, body temperature in dynamics, visually - the state of the nasopharynx, the manifestation of clinical symptoms (sore throat, headaches, difficulty swallowing food, aphonia, and other signs) in dynamics, the functional state of internal organs (percussion, palpation and auscultation). study of one patient - 4 weeks
Primary Laboratory research methods. All examined children will undergo general clinical examination and pharyngoscopy. Additionally, all patients will have tonsil swabs for bacteriological examination (bacteriological culture, n x 104/mL ) according to the standard technique. Also, swabs from the nasopharynx will be taken for viral lesions by the standard method - PCR (polymerase chain reaction). The research will be carried out in specialized laboratories. study of one patient - 2 weeks
Primary Experimental clinical stage. Bacteriophage therapy. Comprehensive outpatient treatment will be based on standard clinical guidelines. Patients will be prescribed antibiotic therapy based on possible pathogens. Patients will receive bacteriophage therapy using a liquid pyobacteriophage complex (liquid pyobacteriophage complex - PCL), through nebulizer inhalation to irrigate the mucous membranes of the tonsils. Just 5 ml PCL for 10 minutes once every 5 days. Efficacy will be studied based on immunological studies.A study of cellular (class of T-lymphocytes, Inflammatory cytokines (e.g., IL-1,2,4,5,6,11,13 - U/ml) and TNF-a) and humoral ( IgA / IgM / IgG -IU/mL) immunity in children will be carried out, using (Enzyme Linked Immunosorbent Assay) ELISA which is an immunoassay, suited to the determination of antibodies in the field of infectious serology. study of one patient - 4 weeks
Secondary The second stage of the study (statistical). The results will be analyzed using a statistical program based on Excel 2017 (Microsoft Office 2017). Clinical signs will be calculated as a percentage (%) incidence. We will calculate the chi-square (?2) test or Fisher's exact test (for expected values <5) to assess if certain pairs of microbes are more common than expected by chance in bacteriological examination. In addition, we will use the Kruskal-Wallis test to compare the average delay between disease onset and sample collection between samples containing one or more organisms. When evaluating immunological analyzes, characterizing the statistical significance of differences, the Student's t-test will be used with the definition of the confidence interval. The X-square test will be used to assess the frequency of identifying qualitative features. In all analyzes, P = 0.05 was considered significant. 4 weeks
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03704506 - Registration of the Study of Reyanning Mixture Phase 4
Completed NCT04537819 - Study of Imupret Application in the Technology of Delayed Prescription of Antibiotics in Patients With Acute Tonsillitis N/A
Not yet recruiting NCT02715037 - Microbiology of Severe Acute Tonsillitis, Peritonsillar Cellulitis, and Infectious Mononucleosis N/A
Completed NCT01363531 - Clinical Trial for the Assessment of Delayed Antibiotic Treatment Strategies Phase 4
Recruiting NCT03134443 - Evaluate the Efficacy and Safety of Andrographolide Sulfonate in Patients With Acute Tonsillitis Phase 4